Sartorius Stedim Biotech publishes unaudited first quarter results for 2025

• Sales revenue at 745 million euros, up 10.4 percent in constant currencies¹ (reported: 11.7 percent)

• High demand for consumables for biomanufacturing, while customer investment in equipment is still muted; book-to-bill ratio¹ well above 1
• Underlying EBITDA¹ at 229 million euros, EBITDA margin at 30.8 percent; net profit of 85 million euros
• Full-year guidance 2025: Sales revenue increase of approximately 7 percent and underlying EBITDA margin of around 30 to 31 percent projected

• Constant currencies: figures given in constant currencies eliminate the impact of changes in exchange rates by applying the same exchange rate for the current and the previous period
• Organic: organic growth figures exclude the impact from changes in exchange rates and changes in the scope of consolidation
• Order intake: all customer orders contractually concluded and booked during the respective reporting period
• Underlying EBITDA: earnings before interest, taxes, depreciation, and amortization and adjusted for extraordinary items
• Underlying net profit: profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate
• Equity ratio: equity in relation to the balance sheet total
• Ratio of net debt to underlying EBITDA: quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period

For detailed results, please see the tables in the attached file.